Guy Levy bought $10.0M of Parabilis Medicines (PBLS)
Executed Jun 11, disclosed Jun 29, 18 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Jun 29), the stock returned +10.1% (delay-adjusted); from the execution session (Jun 11), -1.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Guy Levy (10% owner) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in Parabilis Medicines, Inc. (PBLS). Across 1 priced purchase filing, the average 21-session return was -1.2% from execution and +10.1% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of PBLS (500,000 sh across 2 lots, as filed), executed Jun 11.
Healthcare · Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for dis…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→